Tag Archives: VBIO

Best Medical Stocks To Own Right Now

With Social Security funding issues around the corner, uncertain market conditions, long-term low interest rates and skyrocketing medical costs, American retirees are facing a laundry list of retirement challenges. The only certainty is that retirement is going to be dramatically different than the retirement previous generations encountered. In order to retire with financial security and dignity, Americans need to make well-informed decisions about when to retire, when to collect Social Security, how to manage their retirement savings and what to do about housing in retirement.  It is this last item, housing in retirement, which often gets the least amount of attention, when in fact, it should be closely scrutinized as a powerful asset.

New research from The American College of Financial Services, The Home Equity and Retirement Income Planning Survey, found that the overwhelming majority, 83 percent of Americans nearing or in retirement, want to remain in their current home for as long as possible. Additionally, the desire to remain in one’s home increased with age. Perhaps somewhat surprisingly, not only did the desire to remain in one’s home increase with age, but the number of years the respondent expected to remain in the home also increased with age. Even if the homeowner needed to relocate later in retirement, almost none of the respondents expressed a desire to rent. This research has also been published in the Journal of Financial Planning – see here.

Best Medical Stocks To Own Right Now: Rockwell Medical Technologies Inc.(RMTI)

Advisors’ Opinion:

  • [By Alex McGuire]

    As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…

    Pharmaceutical Stock Current Share Price April 2017 Gain
    Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
    Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
    Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
    Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
    Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
    Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
    Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
    Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
    Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
    Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%

    The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.

  • [By Lisa Levin]

    Thursday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Keryx Biopharmaceuticals (NASDAQ: KERX) and Rockwell Medical Inc (NASDAQ: RMTI).

Best Medical Stocks To Own Right Now: HCI Group, Inc.(HCI)

Advisors’ Opinion:

  • [By Jim Robertson]

    Small cap Florida insurance stock HCI Group Inc (NYSE: HCI) has taken a hit with shares down around 21% over the past week on predictions that Hurricane Irma would hit Florida albeit sharesrose 2.74%on Friday when it became clear that it would not be as catastrophic as feared:

Best Medical Stocks To Own Right Now: Sonic Corp.(SONC)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap burger stock Sonic Corporation (NASDAQ: SONC) reported fiscal Q1 2018 earnings after the market closed Thursday that exceeded Wall Street expectations. Total revenues were $105.428 million versus $129.551 million assystem same-store sales declined 1.7% – consisting of a 1.6% same-store sales decrease at franchise drive-ins and a 3.2% decrease at company drive-in. Net income totaled $11.4 million versus net income of $13.1 million. The CEO commented:

  • [By Peter Graham]

    Small cap burger stock Sonic Corporation (NASDAQ: SONC) reported fiscal Q3 2017 earnings after the market closed yesterday with earnings exceeding Wall Street expectations. GAAP revenue was $123.990 million versus $165.239 million as system same-store sales declined 1.2% consisting of a 1.1% same-store sales decrease at franchise drive-ins and a 3.2% decrease at company drive-ins. Net income totaled $18.8 million versus net income of $15.4 million. The Chairman/CEO commented:

  • [By Peter Graham]

    After the market closed yesterday, small cap burger stock Sonic Corporation (NASDAQ: SONC) reported fiscalQ2 2017 earnings with shares falling moderately in after hours trading as the top line missed and the bottom line met expectations. However, it appears analysts are zeroing in on the system same-store sales comps down 7.4% versus expectations for a fall of 4.3%. The decline was comprised of a7.3% same-store sales decline at franchise drive-ins and a decline of 8.9% at company drive-ins.

  • [By Peter Graham]

    A long term performance chart shows shares of newcomers Shake Shack and California based IPO Habit Restaurants both underperforming or below their IPO close prices whilemore established small capburger stocks Red Robin Gourmet Burgers, Inc (NASDAQ: RRGB) and Sonic Corporation (NASDAQ: SONC) were big outperformers up until more recently:

  • [By ]

    Among McDonald’s main rivals, identified by FactSet, are Starbucks Corp. (SBUX) , down almost 5.5%; Yum! Brands (YUM) , which owns KFC, Pizza Hut and Taco Bell, up 32%; and burger chain Sonic Corp. (SONC) , down about 2%. These are all year-over-year percentages.

  • [By Peter Graham]

    A long term performance chart shows shares of small caps Habit Restaurants and Shake Shack Inc (NYSE: SHAK) below their IPO prices while more established burger stocks Red Robin Gourmet Burgers, Inc (NASDAQ: RRGB) and Sonic Corporation (NASDAQ: SONC)have seen their performance drift downward last year or the year before:

Best Medical Stocks To Own Right Now: Sack Lunch Productions (SAKL)

Advisors’ Opinion:

  • [By James E. Brumley]

    Tuesday morning, Sack Lunch Productions Inc (OTCMKTS:SAKL) posted its results for the third quarter (ending September 30th) of the year. They were as strong as you might suspect, with the top line rolling in at $5.35 million, and $142,983 of that turning into net income. That top and bottom line were actually down a bit from the year-ago comparables, though investors should bear in mind that the third quarter of last year was an unusually tough comparison of $6.02 million in sales, and income of $688,845. That was a true breakout quarter for the company’s signature event – Slide the City – and many participants may have come simply to see what it was. The follow-up year (this year), SAKL may not have had the same curiosity factor compelling people to attend.

    Sack Lunch Productions, for the unfamiliar, it’s the name behind event-oriented businesses called Slide the City, Lantern Fest, The Dirty Dash, the Color Me Rad 5K run, and most recently, the Trike Riot. Those are a 1000-foot Slip-n-Slide, a flying lantern release, a mud run, a color-splashing fun run, and a tricycle riding course for kids of all ages and sizes. The events aren’t just fun – they’re FUN!

    They’re also surprisingly profitable. While attendance and per-participant revenue varies, with the average revenue of $30 per participant being at the low end of the scale ( as is the average event attendance of 2500), gross revenue of $75,000 per event is a low-end expectation…

    … not that SAKL hasn’t done some more number crunching of its own. This year, it expects to host roughly 250 events and drive $17 million worth of revenue per event, up about 80% from 2015’s top line. Some of those are being put on by Sack Lunch Productions itself, while others are being hosted by franchisees. Whatever the case, that works out to average revenue of $72,000 per event, with the franchised ones being low-cost to no-cost events for SAKL.

    Regardless, the trend is an impressive one, all

Best Medical Stocks To Own Right Now: Vitality Biopharma (VBIO)

Advisors’ Opinion:

  • [By James E. Brumley]

    Are you an investor interested in learning more about Vitality Biopharma Inc (OTCMKTS:VBIO)? Or, are you looking to take your first look at VBIO? A SeeThruEquity research report posted in August not only has you covered, it underscores all of its hidden bullishness. The report also explains a very impressive target price for Vitality Biopharma shares. In short, the research outfit now believes the stock will see $2.00 per share sooner than later, based on its pipeline and potential market penetration. That’s 38% higher than its current value.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

  • [By James E. Brumley]

    Investors who were looking to learn a little more about up-and-coming drug development company Vitality Biopharma Inc (OTCMKTS:VBIO) may want to mark December 8th on their calendar…. if they’re going to be in the Los Angeles area that day anyway. The company will be making a presentation that day, at the annual LD Micro Main Event. Interested and approved investors can attend the VBIO presentation by registering beforehand with LD Micro.

    Vitality Biopharma has found a way to make cannabinoid-based pharmaceuticals without the usual downside of cannabinoids. Namely, Vitality Biopharma’s version of cannabinoids are non-psychotropic, meaning larger, more effective dosing is possible without the ‘high’. It’s this little detail that takes cannabinoid medicine — already the most compelling frontier in the world of pharma — to the next level. There’s a reason some people think the cannabinoid market could be worth $20 billion by 2020.

    The idea was significantly advanced in early November. In eight of the nine states voters were asked about legalization of marijuana (for one reason or another), voters said yes….. four for recreational use, and four for medical use. In eight of those nine states, the measures passed. Marijuana is legal in more than half the United States now, and we’re en route to a decided majority in the foreseeable future.

    VBIO didn’t necessarily need a sweeping victory at the ballot box, but each time marijuana wins, it seems to advance the discussion of the power of cannabinoids as medicine.

    Investors will be able to learn more about Vitality Biopharma’s work in that arena on Thursday of this week. On that day — 8 AM PST / 11 AM EST — at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Robert Brooke, CEO of Vitality Biopharma, will be making a presentation as well as meeting with current and prospective investors.

    LD Micro was founded in 2006 with the sole purpose of being an independent resource in t

  • [By James E. Brumley]

    In mid-September, Vitality Biopharma Inc (OTCMKTS:VBIO) announced it was going to take aim at the development of an alternative to opioids as a means of treating pain. At the time, there was little doubt that the company’s cannabinoid science was capable of doing so. What wasn’t clear to VBIO shareholders was exactly how that might happen…. meaning what sort of drug might Vitality Biopharma come up with.

    We got the first of what will likely be several answers to the question today. Per today’s press release, Vitality Biopharma intends to come up with a treatment for narcotic bowel syndrome, which is a severe form of (ironically enough) opiate-induced abdominal pain.

    As a refresher, Vitality Biopharma was the name we introduced to you back on August 8th, pointing out it had developed a whole new way of making cannabinoid-based medicines. Their versions offer all the upsides of cannabinoids, but without the psychotropic (“getting high’) effects, and without some of the common downsides associated with these pharmaceuticals… like mouth and skin lesions.

    There are even bigger advantages to Vitality Biopharma’s science, however. Namely, since these drugs are prodrugs and aren’t activated until in the body, they allow for targeted delivery to the GI tract (yet can also selectively target other body parts, even as far away from the GI tract as the brain). Perhaps more than anything though, these drugs are orally-administered by virtue of being highly soluble, making them easy to use.

    It’s this nuance that makes Vitality Biopharma’s recently-announced intention so interesting, and compelling.

    Studies have found that up to 81% of patients treated with opiates have functional bowel disorders, with more than half — 58% to be exact — of opiate users reporting chronic abdominal pain stemming from the use of their prescribed painkillers. Considering 200 million opioid prescriptions are filled every year in the United States alo

  • [By Matthew Briar]

    Back in September, Vitality Biopharma Inc (OTCMKTS:VBIO) CEO Robert Brooke officially announced his company would be entering the painkiller market, specifically taking aim at the development of an alternative to opioids. His specific words? “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”

Best Medical Stocks To Own Right Now: Ono Pharmaceutical Co., Ltd. (OPHLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.

Top Stocks To Own For 2018

Pondering Snap’s IPO over laser tag and paintball Even concerns about Snapchat’s slowing user growth aren’t stopping investors from clamoring for its stock.

Snap, the parent company of Snapchat, priced its initial public offering at $17 a share on Wednesday. It had previously proposed a range of $14 to $16 a share.

That will reportedly give Snap a market value of nearly $24 billion, making it the largest U.S. tech IPO since Facebook (FB, Tech30).

Reps for Snap did not immediately respond to a request for comment.

“The demand for the Snap IPO has been very, very strong,” says Jeff Zell, an analyst with IPO Boutique, a research firm. “Even the original naysayers and detractors from the deal have pretty much softened their negativity.”

Top Stocks To Own For 2018: Vitality Biopharma (VBIO)

Advisors’ Opinion:

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

  • [By James E. Brumley]

    Investors who were looking to learn a little more about up-and-coming drug development company Vitality Biopharma Inc (OTCMKTS:VBIO) may want to mark December 8th on their calendar…. if they’re going to be in the Los Angeles area that day anyway. The company will be making a presentation that day, at the annual LD Micro Main Event. Interested and approved investors can attend the VBIO presentation by registering beforehand with LD Micro.

    Vitality Biopharma has found a way to make cannabinoid-based pharmaceuticals without the usual downside of cannabinoids. Namely, Vitality Biopharma’s version of cannabinoids are non-psychotropic, meaning larger, more effective dosing is possible without the ‘high’. It’s this little detail that takes cannabinoid medicine — already the most compelling frontier in the world of pharma — to the next level. There’s a reason some people think the cannabinoid market could be worth $20 billion by 2020.

    The idea was significantly advanced in early November. In eight of the nine states voters were asked about legalization of marijuana (for one reason or another), voters said yes….. four for recreational use, and four for medical use. In eight of those nine states, the measures passed. Marijuana is legal in more than half the United States now, and we’re en route to a decided majority in the foreseeable future.

    VBIO didn’t necessarily need a sweeping victory at the ballot box, but each time marijuana wins, it seems to advance the discussion of the power of cannabinoids as medicine.

    Investors will be able to learn more about Vitality Biopharma’s work in that arena on Thursday of this week. On that day — 8 AM PST / 11 AM EST — at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Robert Brooke, CEO of Vitality Biopharma, will be making a presentation as well as meeting with current and prospective investors.

    LD Micro was founded in 2006 with the sole purpose of being an independent resource in t

  • [By James E. Brumley]

    In mid-September, Vitality Biopharma Inc (OTCMKTS:VBIO) announced it was going to take aim at the development of an alternative to opioids as a means of treating pain. At the time, there was little doubt that the company’s cannabinoid science was capable of doing so. What wasn’t clear to VBIO shareholders was exactly how that might happen…. meaning what sort of drug might Vitality Biopharma come up with.

    We got the first of what will likely be several answers to the question today. Per today’s press release, Vitality Biopharma intends to come up with a treatment for narcotic bowel syndrome, which is a severe form of (ironically enough) opiate-induced abdominal pain.

    As a refresher, Vitality Biopharma was the name we introduced to you back on August 8th, pointing out it had developed a whole new way of making cannabinoid-based medicines. Their versions offer all the upsides of cannabinoids, but without the psychotropic (“getting high’) effects, and without some of the common downsides associated with these pharmaceuticals… like mouth and skin lesions.

    There are even bigger advantages to Vitality Biopharma’s science, however. Namely, since these drugs are prodrugs and aren’t activated until in the body, they allow for targeted delivery to the GI tract (yet can also selectively target other body parts, even as far away from the GI tract as the brain). Perhaps more than anything though, these drugs are orally-administered by virtue of being highly soluble, making them easy to use.

    It’s this nuance that makes Vitality Biopharma’s recently-announced intention so interesting, and compelling.

    Studies have found that up to 81% of patients treated with opiates have functional bowel disorders, with more than half — 58% to be exact — of opiate users reporting chronic abdominal pain stemming from the use of their prescribed painkillers. Considering 200 million opioid prescriptions are filled every year in the United States alo

  • [By Phil Saunders]

    Vitality Biopharma, Inc. (OTCBB: VBIO) recent ascent as a strong small cap player in Cannabis pharma, is part of a boom in Cannabis-based pharmaceuticals making announcements about unique and innovative delivery systems being tested for such ailments as Epilepsy, Multiple Sclerosis, and Crohns disease. But it is important to understand how the industry is evolving in the United States and Canada and what that might mean when realizing valuation and the evolution of government policies which still vary from jurisdiction to jurisdiction, making access to Cannabis and the pricing model still a big question moving forward.

  • [By Matthew Briar]

    Back in September, Vitality Biopharma Inc (OTCMKTS:VBIO) CEO Robert Brooke officially announced his company would be entering the painkiller market, specifically taking aim at the development of an alternative to opioids. His specific words? “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”

Top Stocks To Own For 2018: On Assignment Inc.(ASGN)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewslettersuggested suggested small cap employment services stockOn Assignment, Inc (NYSE: ASGN) as a short trade thats already turned profitable for us:

Top Stocks To Own For 2018: Technology Select Sector SPDR ETF (XLK)

Advisors’ Opinion:

  • [By ]

    What My System Flagged As A Buy This Week
    It’s no secret that the technology sector has had an incredible year so far — the SPDR Technology Select ETF (NYSE: XLK) is up over 31% year-to-date, compared with the S&P 500’s 14% return.

  • [By Craig Jones]

    Kevin Kelly, the managing partner at Kelly & Co., spoke on Bloomberg Markets about a bullish options trade in Technology Select Sector SPDR Fund (NYSE: XLK).

  • [By Wayne Duggan]

    High-flying tech stocks were hammered Wednesday, sending the Technology Select Sector SPDR Fund (NYSE: XLK) down more than 2.5 percent and the Nasdaq down 1.4 percent, its worst day of trading since August 17.

  • [By Money Morning News Team]

    If the price is keeping you out of GOOGL, take a look at theTechnology SPDR ETF (NYSE Arca: XLK), where you get to hold shares of many of these top tech companies at a fraction of the cost.

Top Stocks To Own For 2018: Dunkin' Brands Group, Inc.(DNKN)

Advisors’ Opinion:

  • [By WWW.USATODAY.COM]

    While McDonald’s (NYSE: MCD) and Dunkin’ Brands’ (NASDAQ: DNKN) Dunkin’ Donuts both now sell premium espresso-based beverages along with other fancy coffee drinks, people don’t view those brands the way they see Starbucks. The Seattle-based coffee chain exists in its own world, where it can sell out of $10 cups of whisky-barrel-aged coffee while it opens more than a thousand Reserve stores selling pricier drinks than its normal, already expensive beverage lineup.

  • [By Ben Levisohn]

    Dunkin’ Brands Group (DNKN) has dropped 3.5% to $54.16 after getting cut to Sell from Neutral at Goldman Sachs.

    Morgan Stanley (MS) has risen 1.1% to $42.95 after getting upgraded to Buy from Hold at Deutsche Bank.

  • [By Ben Levisohn]

    The market is treating Chipotle as if it is an Amazon, Tesla, Apple or Google, when in fact all they do is make burritos. With the money it would cost you to buy Chipotle today @ $14 billion dollars you could buy Wendy’s (WEN), Cheesecake Factory (CAKE), Papa John’s International (PZZA), and Dunkin’ Brands (DNKN). Chipotle would need to generate at least $24 in earnings per share in order to justify the current market cap — they are not even expected to generate half of that next year. Chipotle is expected to report Q1 on April 25 and the market, in my opinion, has already more than priced in good news.

  • [By John Udovich]

    While theMacys Thanksgiving Day parade sponsored by Macy’s, Inc (NYSE:M) is the most well known corporate sponsoredThanksgiving parade,Dunkin Brands Group Inc (NASDAQ:DNKN) and McDonald’s Corporation (NYSE:MCD) also sponsor parades in major USA cities that will help them grab some extra consumer attention and perhaps help the bottom line a bit.

Top Stocks To Own For 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

Top 10 Heal Care Stocks To Own For 2018

By Scott Tzu with Parke Shall

When a company is in a distressed situation, a lot of times it’s not going to come out and tell the public that it is looking at a reorganization or considering filing bankruptcy. As investors, we are often left to draw our own conclusions based on piecemeal that we can obtain regarding the company in question. We believe the signs and signals continue to indicate to us that Concordia Healthcare (NASDAQ:CXRX) is not a stock to be in, has limited turnaround prospects, and could very well be heading for restructuring.

By now, most readers will find themselves familiar with the CXRX story, but for those who are not, we will give you a small briefing. Concordia is one of many pharmaceutical companies that tried to expand by rolling up other corporations once the cost of debt became very cheap. It used a hybrid style pricing model, where it raised the price of several key drugs after acquiring them in order to bet it all on the company’s future cash flows instead of the mounting pile of debt that the company was accruing. When presenting earnings each quarter, CXRX used similar non-GAAP accounting treatments to give the impression that acquisition costs and one time costs would not be a factor. Now, like Valeant (NYSE:VRX), as questions start to rise about the company’s product line, all eyes turn to the balance sheet, which is in severe distress.

Top 10 Heal Care Stocks To Own For 2018: Outerwall Inc.(OUTR)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of Netflix at all time highswhile potential performance peer or competitor Amazon.com, Inc (NASDAQ: AMZN) has continueda more steadyrise and small cap Outerwall Inc (NASDAQ: OUTR), which owned the Redbox business,was swallowed up Apollo Global Management, LLC (NYSE: APO) late last year:

  • [By Jake L’Ecuyer]

    Equities Trading DOWN
    Shares of Outerwall (NASDAQ: OUTR) were down 16.03 percent to $47.00 after the company lowered its forecast for the third quarter and full year. Werner Enterprises (NASDAQ: WERN) shares tumbled 4.71 percent to $23.26 after the company issued a weak third-quarter profit forecast. Bank of America downgraded the stock from Buy to Neutral. Pandora Media (NYSE: P) down, falling 1.71 percent to $23.58 as the company announced its plans to sell 14 million shares of common stock, including 4 million shares from current stockholders.

  • [By Monica Gerson]

    Shares of Outerwall Inc (NASDAQ: OUTR) surged over 8 percent in Monday’s after-hours trading session following news for investors the company has begun the process of exploring strategic and financial alternatives. Outerwall’s Board also announced the raising of the company’s quarterly dividend from $0.30 to $0.60 per share. Outerwall shares jumped 8.11 percent to $37.18 in the after-hours trading session.

  • [By Monica Gerson]

    Outerwall (NASDAQ: OUTR) dipped 19.33% to $45.15 in the pre-market session after the company lowered its forecast for the third quarter and full year.

  • [By Peter Graham]

    A long term performance chart shows shares of Netflix close to all time highsgoing into earnings while potential performance peer or competitor Amazon.com, Inc (NASDAQ: AMZN) has continueda more steadyrise and small cap Outerwall Inc (NASDAQ: OUTR), which owned the Redbox business,got swallowed up Apollo Global Management, LLC (NYSE: APO) late last year:

Top 10 Heal Care Stocks To Own For 2018: Liberty Interactive Corporation(LVNTA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of General Communication, Inc. (NASDAQ: GNCMA) got a boost, shooting up 63 percent to $33.43 after Liberty Interactive Corporation (NASDAQ: LVNTA) announced plans to acquire General Communication for $1.12 billion.

Top 10 Heal Care Stocks To Own For 2018: Spark Networks, Inc.(LOV)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap dating site stock Match Group Inc (NASDAQ: MTCH), which was spun off from media and Internet stock IAC/InterActiveCorp (NASDAQ: IAC) and is a peer or remaining dating stock Spark Networks Inc (NYSEMKT: LOV), is the eight most shorted stock on theNASDAQ with short interest of 43.96% according to Highshortnterest.com.

Top 10 Heal Care Stocks To Own For 2018: Washington Federal, Inc.(WAFD)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    The six companies that met the criterion are:

    Oshkosh Corp (NYSE: OSK). Phillips 66 (NYSE: PSX). SpartanNash Co (NASDAQ: SPTN). Suncor Energy Inc. (USA) (NYSE: SU). Washington Federal Inc. (NASDAQ: WAFD). Barnes & Noble, Inc. (NYSE: BKS).
    Oshkosh

    Oshkosh is a manufacturer of specialty vehicles and vehicle bodies and is based in Wisconsin. The company operates under four business segments, namely access equipment, defense, fire and emergency, and commercial.

Top 10 Heal Care Stocks To Own For 2018: Huntsman Corporation(HUN)

Advisors’ Opinion:

  • [By Lee Jackson]

    Huntsman Corp. (NYSE: HUN) had its executive chairman selling stock last week. Jon Huntsman parted with 600,000 shares, and the share priceranged from $17.25 to $17.27. The total for the trade was posted at $10 million.The company manufactures and sells differentiated organic and inorganic chemical products worldwide. The stock traded Friday at $18.10, so some left on that table as well.

  • [By Paul Ausick]

    Venator Materials PLC is a maker of titanium dioxide pigments and additives. The company is being spun out of Huntsman Corp. (NYSE: HUN) and plans to offer 22.7 million shares in an expected price range of $20 to $21, raising $465 million at an implied market cap of $2.18 billion. Underwriters include Citi, Goldman Sachs, BofA/Merrill Lynch, J.P. Morgan, Barclays, Deutsche Bank, UBS Investment Bank, RBC Capital Markets, Moelis & Company, HSBC Corp., Nomura Securities, SunTrust Robinson Humphrey, Academy Securities, and Commerzbank Capital. Shares are scheduled to price Wednesday and begin trading Thursday on the New York Stock Exchange under the ticker symbol VNTR.

Top 10 Heal Care Stocks To Own For 2018: Helmerich & Payne, Inc.(HP)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Western Digitalnow expects Dec-Q revenue of $4.75Bn, gross margin of 36%, tax rate of 13%, and EPS between $2.10-$2.15; versus ~$4.71Bn, 36%, 14-16%, and $1.85-$1.95, respectively. We believe that the Dec-Q guidance update is mostly attributed to the resolution of IP disputes with Samsung and better-than-expected execution by Western Digital; meaning, we do not expect much read-through benefit forSeagate Technology (STX) or HP Inc (HP) (both Equal Weight-rated stocks)…

  • [By Reuben Gregg Brewer]

    Helmerich & Payne, Inc.(NYSE:HP) has an impressive dividend record, particularly when you take into consideration that it operates in the highly cyclical oil and gas services industry. The problem for investors, though, is that a dividend decision a few years ago obscures the income story here. This is one stock where the trend isn’t what it seems, and a little more analysis is needed to understand Helmerich & Payne’s true dividend potential.

  • [By Reuben Gregg Brewer]

    The energy sector is feeling the pinch of low oil and natural gas prices, which has been a headwind for oil field services industry stalwart Helmerich & Payne, Inc. (NYSE:HP) and dragged down investor sentiment for midstream sector players Enterprise Products Partners L.P. (NYSE:EPD) and Buckeye Partners, L.P. (NYSE:BPL). But each of these companies has a long history of increasing dividends annually, which means that the bad news today is likely to be good news for dividend lovers looking for big yields.

  • [By Wayne Duggan]

    While Loop maintains a Buy rating on all of the stocks mentioned above, Guggenheim analyst Michael LaMotte isn’t quite so bullish on the sector. Earlier this week, LaMotte downgraded the following oil services stocks from Buy to Neutral:

    Baker Hughes Incorporated (NYSE: BHI)
    Fairmount Santrol Holdings Inc (NYSE: FMSA)
    Helmerich & Payne, Inc. (NYSE: HP)
    Nabors Industries Ltd. (NYSE: NBR)
    Schlumberger Limited. (NYSE: SLB)
    Halliburton
    Superior Energy Services

    Guggenheim also cut its 2017 oil price forecast from $55 to $48/bbl.

Top 10 Heal Care Stocks To Own For 2018: Marathon Oil Corporation(MRO)

Advisors’ Opinion:

  • [By Dustin Blitchok]

    Marathon Oil Corporation (NYSE: MRO) was upgraded from Neutral to Positive at Susquehanna on Friday after the oil giant sold off its Canadian subsidiary for $2.5 billion and bought 71,000 acres of oil fields in New Mexico for $1.1 billion.

  • [By Ben Levisohn]

    Marathon Oil (MRO) tumbled to the bottom of the S&P 500 today after oil tumbled after data pointed to higher inventories of crude.

    Agence France-Presse/Getty Images

    Marathon Oildropped 8.7% to $14.87, while the S&P 500 fell 0.2% to 2,362.98, as Front Month Nymex Crude futures for April delivery slid 5.4% to $50.28., leading some to wonder if the price oil could drop below $50 a barrel.

    It wasn’t just Marathon that got clipped as the eight worst-performing stocks in the S&P 500 came from the energy sector, including Murphy Oil (MUR), which fell 6.7% to $25.87, Devon Energy (DVN), which slid 6.5% to $40.72, and Chesapeake Energy (CHK), which stumbled 6.1% to $4.94. No surprise, then, that the Energy Select Sector SPDR ETF (XLE) slumped 2.6% to $69.65.

    The oil rout began after the U.S. Energy Information Administration reported that U.S. oil inventories rose by 8.2 million barrels to reach $518.4 million, a record level.

    Marathon Oil’s market capitalization fell to $12.6 billion today from $13.8 billion yesterday. It reported a net loss of $2.1 billion on sales of $4.1 billion in 2016.

  • [By WWW.THESTREET.COM]

    Cramer said he tried to buck this trend by investing in EOG Resources (EOG) and Marathon Oil (MRO) but was wrong on both counts. In the case of EOG, even having the best properties wasn’t enough to ward off the collapse in oil prices. Meanwhile, Marathon’s decision to spin off its refining business left it with no cushion to stem its losses.

  • [By Paul Ausick]

    Marathon Oil Corp. (NYSE: MRO) dropped about 1.6% Friday to post a new 52-week low of $11.41 after closing Thursday at $11.59. The 52-week high is $19.28. Volume was about 30% lower than the daily average of about 13.7 million shares. The company had no specific news.

  • [By Shanthi Rexaline]

    The bulking up strategy did not work well for the company over the years, as it saw its market share dwindle and profitability erode. In 1982, in a diversification bid, the company picked up Marathon Oil Corporation (NYSE: MRO) and renamed itself as USX.

  • [By Paul Ausick]

    Marathon Oil Corp. (NYSE: MRO) dropped about 1.7% Tuesday to post a new 52-week low of $11.33 after closing Monday at $11.53. The 52-week high is $19.28. Volume was nearly 50% higher than the daily average of about 13.7 million shares. The company had no specific news.

Top 10 Heal Care Stocks To Own For 2018: Ternium S.A.(TX)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Shares of Ternium SA (NYSE:TX) jumped on Wednesday: up more than 10% by 2:30 p.m. EST. While the steelmaker reported weaker-than-expected earnings after the closing bell yesterday, it provided optimistic guidance and announced a compelling acquisition.

Top 10 Heal Care Stocks To Own For 2018: Vitality Biopharma (VBIO)

Advisors’ Opinion:

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

  • [By James E. Brumley]

    Investors who were looking to learn a little more about up-and-coming drug development company Vitality Biopharma Inc (OTCMKTS:VBIO) may want to mark December 8th on their calendar…. if they’re going to be in the Los Angeles area that day anyway. The company will be making a presentation that day, at the annual LD Micro Main Event. Interested and approved investors can attend the VBIO presentation by registering beforehand with LD Micro.

    Vitality Biopharma has found a way to make cannabinoid-based pharmaceuticals without the usual downside of cannabinoids. Namely, Vitality Biopharma’s version of cannabinoids are non-psychotropic, meaning larger, more effective dosing is possible without the ‘high’. It’s this little detail that takes cannabinoid medicine — already the most compelling frontier in the world of pharma — to the next level. There’s a reason some people think the cannabinoid market could be worth $20 billion by 2020.

    The idea was significantly advanced in early November. In eight of the nine states voters were asked about legalization of marijuana (for one reason or another), voters said yes….. four for recreational use, and four for medical use. In eight of those nine states, the measures passed. Marijuana is legal in more than half the United States now, and we’re en route to a decided majority in the foreseeable future.

    VBIO didn’t necessarily need a sweeping victory at the ballot box, but each time marijuana wins, it seems to advance the discussion of the power of cannabinoids as medicine.

    Investors will be able to learn more about Vitality Biopharma’s work in that arena on Thursday of this week. On that day — 8 AM PST / 11 AM EST — at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Robert Brooke, CEO of Vitality Biopharma, will be making a presentation as well as meeting with current and prospective investors.

    LD Micro was founded in 2006 with the sole purpose of being an independent resource in t

  • [By Phil Saunders]

    Vitality Biopharma, Inc. (OTCBB: VBIO) recent ascent as a strong small cap player in Cannabis pharma, is part of a boom in Cannabis-based pharmaceuticals making announcements about unique and innovative delivery systems being tested for such ailments as Epilepsy, Multiple Sclerosis, and Crohns disease. But it is important to understand how the industry is evolving in the United States and Canada and what that might mean when realizing valuation and the evolution of government policies which still vary from jurisdiction to jurisdiction, making access to Cannabis and the pricing model still a big question moving forward.

  • [By James E. Brumley]

    Are you an investor interested in learning more about Vitality Biopharma Inc (OTCMKTS:VBIO)? Or, are you looking to take your first look at VBIO? A SeeThruEquity research report posted in August not only has you covered, it underscores all of its hidden bullishness. The report also explains a very impressive target price for Vitality Biopharma shares. In short, the research outfit now believes the stock will see $2.00 per share sooner than later, based on its pipeline and potential market penetration. That’s 38% higher than its current value.

  • [By Matthew Briar]

    Back in September, Vitality Biopharma Inc (OTCMKTS:VBIO) CEO Robert Brooke officially announced his company would be entering the painkiller market, specifically taking aim at the development of an alternative to opioids. His specific words? “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”

  • [By Jim Robertson]

    Yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announcedthe filing of an international patent application that describes compounds discovered to be effective for neural repair treatments. The underlying patent rights were assigned to Vitality Biopharma in March 2016 and are based on work performed by the Myelin Repair Foundation (MRF) -a non-profit disease research organization that was dedicated to developing regenerative therapies for multiple sclerosis.

Top 10 Heal Care Stocks To Own For 2018: Fifth Street Asset Management Inc.(FSAM)

Advisors’ Opinion:

  • [By Lisa Levin] Related LOV Match Group And Spark Networks: A Valentine's Day Case Study 20 Biggest Mid-Day Losers For Thursday
    Related VKTX 15 Biggest Mid-Day Losers For Tuesday 18 Biggest Mid-Day Losers For Wednesday Companies Reporting Before The Bell
    Canadian Solar Inc. (NASDAQ: CSIQ) is expected to report its quarterly earnings at $0.32 per share on revenue of $690.27 million.
    General Mills, Inc. (NYSE: GIS) is projected to report its quarterly earnings at $0.71 per share on revenue of $3.84 billion.
    Coca-Cola European Partners Plc (NYSE: CCE) is estimated to report its quarterly earnings at $0.45 per share on revenue of $2.72 billion.
    Lands' End, Inc. (NASDAQ: LE) is expected to report its quarterly earnings at $0.35 per share on revenue of $459.43 million.
    Francesca's Holdings Corp (NASDAQ: FRAN) is estimated to report its quarterly earnings at $0.37 per share on revenue of $145.91 million.
    Cheetah Mobile Inc (ADR) (NYSE: CMCM) is projected to report its quarterly earnings at $0.06 per share on revenue of $178.04 million.
    Neogen Corporation (NASDAQ: NEOG) is estimated to report its quarterly earnings at $0.27 per share on revenue of $90.05 million.
    Lennar Corporation (NYSE: LEN) is projected to post earnings for its first quarter.
    Fifth Street Asset Management Inc (NASDAQ: FSAM) is expected to report its quarterly earnings at $0.14 per share on revenue of $25.12 million.

     

  • [By Jordan Wathen]

    Last week,The Wall Street Journal broke the news that Fifth Street Asset Management (NASDAQ:FSAM) was on the auction block, apparently for the second time.

Top 5 Bank Stocks To Watch For 2018

Naperville, IL, based Investment company PL Capital Advisors, LLC buys Southern National Bancorp of Virginia Inc, sells Peoples Bancorp Inc (Marietta OH), United Financial Bancorp Inc, Eastern Virginia Bankshares Inc, Riverview Bancorp Inc, BCB Bancorp Inc during the 3-months ended 2017-06-30, according to the most recent filings of the investment company, PL Capital Advisors, LLC. As of 2017-06-30, PL Capital Advisors, LLC owns 30 stocks with a total value of $380 million. These are the details of the buys and sells.

New Purchases: SONA, Added Positions: FNB, Reduced Positions: PEBO, UBNK, RVSB, BCBP, Sold Out: EVBS, MOFG,

For the details of PL Capital Advisors, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=PL+Capital+Advisors%2C+LLC

These are the top 5 holdings of PL Capital Advisors, LLCBanc of California Inc (BANC) – 3,401,719 shares, 19.25% of the total portfolio. First Merchants Corp (FRME) – 811,333 shares, 8.57% of the total portfolio. MutualFirst Financial Inc (MFSF) – 715,773 shares, 6.72% of the total portfolio. BankFinancial Corp (BFIN) – 1,630,170 shares, 6.4% of the total portfolio. Horizon Bancorp (IN) (HBNC) – 889,142 shares, 6.17% of the total portfolio. New Purchase: Southern National Bancorp of Virginia Inc (SONA)

PL Capital Advisors, LLC initiated holdings in Southern National Bancorp of Virginia Inc. The purchase prices were between $16.32 and $18.41, with an estimated average price of $17.32. The stock is now traded at around $16.91. The impact to the portfolio due to this purchase was 0.55%. The holdings were 118,385 shares as of 2017-06-30.

Top 5 Bank Stocks To Watch For 2018: Affimed N.V.(AFMD)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares rose 47.1 percent to $3.22 in pre-market trading after jumping 54.23 percent on Wednesday.
    Digital Power Corporation (NYSE: DPW) rose 27.6 percent to $0.800 in pre-market trading after gaining 9.79 percent on Wednesday.
    Social Reality Inc (NASDAQ: SRAX) shares rose 23.1 percent to $7.16 in the pre-market trading session after surging 37.59 percent on Wednesday.
    China Auto Logistics Inc (NASDAQ: CALA) rose 16.9 percent to $4.15 in pre-market trading after gaining 4.11 percent on Wednesday.
    Riot Blockchain Inc (NASDAQ: RIOT) rose 15.1 percent to $18.40 in pre-market trading after climbing 42.01 percent on Wednesday.
    Seven Stars Cloud Group Inc (NASDAQ: SSC) rose 14.5 percent to $2.85 in the pre-market trading session after gaining 0.40 percent on Wednesday.
    Affimed NV (NASDAQ: AFMD) shares rose 14.3 percent to $2.40 in pre-market trading after gaining 4.88 percent on Wednesday.
    Corecivic Inc (NYSE: CXW) rose 10.2 percent to $25.56 in pre-market trading after climbing 0.65 percent on Wednesday.
    LM Funding America, Inc. (NASDAQ: LMFA) rose 9.6 percent to $3.30 in pre-market trading after surging 34.98 percent on Wednesday.
    U.S. Global Investors, Inc. (NASDAQ: GROW) rose 7.2 percent to $3.30 in pre-market trading after dropping 8.06 percent on Wednesday.
    Xunlei Ltd (NASDAQ: XNET) rose 6.8 percent to $25.61 in pre-market trading after climbing 11.74 percent on Wednesday.
    Net 1 UEPS Technologies Inc (NASDAQ: UEPS) shares rose 5.9 percent to $13.00 in pre-market trading after gaining 21.34 percent on Wednesday.
    Addus Homecare Corporation (NASDAQ: ADUS) rose 5.5 percent to $35.60 in pre-market trading after gaining 3.69 percent on Wednesday.
    TOP SHIPS Inc (NASDAQ: TOPS) rose 5.2 percent to $0.528 in pre-market trading after falling 10.36 percent on Wednesday.
    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) rose 4.7 percent to $14.11 in pre-market trading. Teva Pharma
  • [By Lisa Levin]

    Shares of Affimed NV (NASDAQ: AFMD) were down around 21 percent to $1.70. Affimed priced its public offering of 10,000,000 of its common shares at $1.80 per common share.

Top 5 Bank Stocks To Watch For 2018: Vitality Biopharma (VBIO)

Advisors’ Opinion:

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

  • [By Matthew Briar]

    Back in September, Vitality Biopharma Inc (OTCMKTS:VBIO) CEO Robert Brooke officially announced his company would be entering the painkiller market, specifically taking aim at the development of an alternative to opioids. His specific words? “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”

  • [By Phil Saunders]

    Vitality Biopharma, Inc. (OTCBB: VBIO) recent ascent as a strong small cap player in Cannabis pharma, is part of a boom in Cannabis-based pharmaceuticals making announcements about unique and innovative delivery systems being tested for such ailments as Epilepsy, Multiple Sclerosis, and Crohns disease. But it is important to understand how the industry is evolving in the United States and Canada and what that might mean when realizing valuation and the evolution of government policies which still vary from jurisdiction to jurisdiction, making access to Cannabis and the pricing model still a big question moving forward.

Top 5 Bank Stocks To Watch For 2018: Tel-Instrument Electronics Corp.(TIK)

Advisors’ Opinion:

  • [By Monica Gerson]

     

    General Mills, Inc. (NYSE: GIS) is expected to report its quarterly earnings at $0.60 per share on revenue of $3.86 billion.
    Pier 1 Imports Inc (NYSE: PIR) is projected to post a quarterly loss at $0.05 per share on revenue of $420.05 million.
    Acuity Brands, Inc. (NYSE: AYI) is estimated to report its quarterly earnings at $2.03 per share on revenue of $847.79 million.
    Monsanto Company (NYSE: MON) is projected to report its quarterly earnings at $2.40 per share on revenue of $4.49 billion.
    Worthington Industries, Inc. (NYSE: WOR) is expected to report its quarterly earnings at $0.64 per share on revenue of $692.48 million.
    Progress Software Corporation (NASDAQ: PRGS) is projected to post its quarterly earnings at $0.29 per share on revenue of $94.64 million.
    UniFirst Corp (NYSE: UNF) is estimated to report its quarterly earnings at $1.34 per share on revenue of $366.28 million.
    Exfo Inc (NASDAQ: EXFO) is expected to post its quarterly earnings at $0.06 per share on revenue of $60.87 million.
    OMNOVA Solutions Inc. (NYSE: OMN) is projected to report its quarterly earnings at $0.14 per share on revenue of $205.40 million.
    8Point3 Energy Partners LP (NASDAQ: CAFD) is estimated to post a quarterly loss at $0.01 per share on revenue of $11.60 million.
    Park Electrochemical Corp. (NYSE: PKE) is expected to report its quarterly earnings at $0.22 per share on revenue of $35.30 million.
    Xplore Technologies Corp. (NASDAQ: XPLR) is projected to post its quarterly earnings at $0.01 per share on revenue of $24.00 million.
    Investors Real Estate Trust (NYSE: IRET) is expected to post its quarterly earnings at $0.14 per share on revenue of $56.87 million.
    Tel-Instrument Electronics Corp. (NYSE: TIK) is estimated to post earnings for the latest quarter.
    Aethlon Medical, Inc. (NASDAQ: AEMD) is expected to post a quarterly loss at $0.20 per share.
    Ossen Innovation Co Ltd (ADR) (NASDAQ: OSN) is projected to post ea

  • [By Lisa Levin]

    Shares of Tel-Instrument Electronics Corp. (NYSE: TIK) got a boost, shooting up 54 percent to $3.55 after the company reported $1 million of new orders.

Top 5 Bank Stocks To Watch For 2018: Century Casinos, Inc.(CNTY)

Advisors’ Opinion:

  • [By Lisa Levin]

    Century Casinos, Inc. (NASDAQ: CNTY) shares dropped 15 percent to $7.77. Century Casinos priced its 4.25 million share offering at $7.50 per share.

Top 5 Bank Stocks To Watch For 2018: AmerisourceBergen Corporation (Holding Co)(ABC)

Advisors’ Opinion:

  • [By Ben Levisohn]

    AmerisourceBergen (ABC) sprinted to the top of the S&P 500 after releasing Street-beating earnings this morning.

    Getty Images

    Shares of AmerisourceBergen jumped 8.8% to $$75.96 today, while the S&P 500 dropped fell 0.7% to 2,097.94.

    Leerink’s David Larsen and Matt Dellelo traces today’s big gain to Amerisource’s big drop following McKesson’s (MCK) earnings last week:

    This morningAmerisourceBergen reported adjusted EPS of $1.30, which was well ahead of Leerink/consensus of $1.22/$1.22. The quality of the beat appears decent, with some pressure in gross margin, completely offset by lower SG&A costs. Given the dramatic reduction in guidance provided byMcKesson (MP), investors had been very cautious heading into the quarter. We are pleased to see that F2017 EPS guidance of $5.63-$5.88 brackets Leerink/consensus estimates of $5.85/$5.82. Brand inflation is now expected to be in the +7-9% range from 10% previously, and F2017 is expected to be back-half loaded. Our first impression of the quarter is that the print and guide are good and there will likely be a relief rally in the shares.

    AmerisourceBergen’s market capitalization rose to $18.1 billion from $16.6 billion yesterday.